External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma.

External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma.

Head Neck. 2015 Dec 17;

Authors: Terra X, Gómez D, García-Lorenzo J, Flores JC, Figuerola E, Mora J, Chacón MR, Quer M, Camacho M, León X, Avilés-Jurado FX

Abstract
BACKGROUND: The main purpose of this study was to validate the prognostic significance of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) in head and neck squamous cell carcinoma (HNSCC) using an independent cohort.
METHODS: Data were evaluated from 153 patients with HNSCC in stages III to IV, who received radiotherapy (RT) or chemoradiotherapy. We quantified soluble TWEAK (sTWEAK) in pretreatment samples using enzyme-linked immunosorbent assay.
RESULTS: The classification tree revealed a cutoff value of 322 pg/mL for sTWEAK to be ideal for discriminating between patients' disease control. Kaplan-Meier curves indicate that the disease-free survival rate in patients with high sTWEAK was significantly higher than in patients with low levels (p = .006, log-rank test). An independent link was identified between low sTWEAK and poor clinical outcome in Cox regression multivariate analysis (hazard ratio = 1.866; 95% confidence interval [CI] = 1.114-3.125; p = .001).
CONCLUSION: Our study highlights the significance of this noninvasive biomarker in the discrimination according to the disease control achieved by patients who received a nonsurgical organ-preservation treatment. © 2015 Wiley Periodicals, Inc. Head Neck, 2015.

PMID: 26676381 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/1JgrdCW
via IFTTT